In this week’s edition of InnovationRx, we look at Eli Lilly’s weight-loss pill stockpiling, scaling stem cell manufacturing, ...
Obesity and diabetes have been two of the greatest public health challenges for decades. Many different diets and fads have promised the public ...
It comes as companies work to build goodwill with Trump, who has emphasized reshoring manufacturing to the U.S. and reducing ...
By now, many people have heard that a diet packed with ultraprocessed foods is not good for us. They have been linked to<a ...
A groundbreaking national poll conducted on behalf of the Diabetes Patient Advocacy Coalition (DPAC) reveals overwhelming ...
Eli Lilly & Co. said Tuesday it's cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity for patients who have to pay for the drug themselves. It said it will also ...
Fourth quarter 2024 net revenue from global sales of IMCIVREE® (setmelanotide) of $41.8 million -- -- On track to report ...
15h
Hosted on MSNKU report: Most infant formulas are bad for babiesA study from the University of Kansas reveals that most U.S. infant formulas contain mainly added sugars instead of the ...
Supplies of high-demand obesity treatments are improving, but that doesn’t mean it's easier to get them. Many employers and ...
A trade group representing compounding pharmacies has filed a lawsuit against the Food and Drug Administration (FDA) for ...
The pharma giant will now offer 7.5mg and 10mg dosages of Zepbound, as well as lower rates for its 2.5mg and 5mg vials.
Metsera’s GLP-1 peptide has a long half-life, meaning it could be administered once a month. The company is ready to scale up.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results